2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer - PubMed (original) (raw)

Review

doi: 10.1089/thy.2015.0020.

Erik K Alexander 2, Keith C Bible 3, Gerard M Doherty 4, Susan J Mandel 5, Yuri E Nikiforov 6, Furio Pacini 7, Gregory W Randolph 8, Anna M Sawka 9, Martin Schlumberger 10, Kathryn G Schuff 11, Steven I Sherman 12, Julie Ann Sosa 13, David L Steward 14, R Michael Tuttle 15, Leonard Wartofsky 16

Affiliations

Review

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Bryan R Haugen et al. Thyroid. 2016 Jan.

Abstract

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer.

Methods: The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations for therapeutic interventions. We developed a similarly formatted system to appraise the quality of such studies and resultant recommendations. The guideline panel had complete editorial independence from the ATA. Competing interests of guideline task force members were regularly updated, managed, and communicated to the ATA and task force members.

Results: The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, management of recurrent and metastatic disease, consideration for clinical trials and targeted therapy, as well as directions for future research.

Conclusions: We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.

PubMed Disclaimer

Figures

<b>FIG. 1.</b>

**FIG. 1.

Algorithm for evaluation and management of patients with thyroid nodules based on US pattern and FNA cytology. R, recommendation in text.

<b>FIG. 2.</b>

**FIG. 2.

ATA nodule sonographic patterns and risk of malignancy.

<b>FIG. 3.</b>

**FIG. 3.

Lymph node compartments separated into levels and sublevels. Level VI contains the thyroid gland, and the adjacent nodes bordered superiorly by the hyoid bone, inferiorly by the innominate (brachiocephalic) artery, and laterally on each side by the carotid sheaths. The level II, III, and IV nodes are arrayed along the jugular veins on each side, bordered anteromedially by level VI and laterally by the posterior border of the sternocleidomastoid muscle. The level III nodes are bounded superiorly by the level of the hyoid bone and inferiorly by the cricoid cartilage; levels II and IV are above and below level III, respectively. The level I node compartment includes the submental and submandibular nodes, above the hyoid bone, and anterior to the posterior edge of the submandibular gland. Finally, the level V nodes are in the posterior triangle, lateral to the lateral edge of the sternocleidomastoid muscle. Levels I, II, and V can be further subdivided as noted in the figure. The inferior extent of level VI is defined as the suprasternal notch. Many authors also include the pretracheal and paratracheal superior mediastinal lymph nodes above the level of the innominate artery (sometimes referred to as level VII) in central neck dissection (341).

<b>FIG. 4.</b>

**FIG. 4.

Risk of structural disease recurrence in patients without structurally identifiable disease after initial therapy. The risk of structural disease recurrence associated with selected clinico-pathological features are shown as a continuum of risk with percentages (ranges, approximate values) presented to reflect our best estimates based on the published literature reviewed in the text. In the left hand column, the three-tiered risk system proposed as the Modified Initial Risk Stratification System is also presented to demonstrate how the continuum of risk estimates informed our modifications of the 2009 ATA Initial Risk System (see Recommendation 48). *While analysis of BRAF and/or TERT status is not routinely recommended for initial risk stratification, we have included these findings to assist clinicians in proper risk stratification in cases where this information is available. FTC, follicular thyroid cancer; FV, follicular variant; LN, lymph node; PTMC, papillary thyroid microcarcinoma; PTC, papillary thyroid cancer.

<b>FIG. 5.</b>

**FIG. 5.

Clinical decision-making and management recommendations in ATA low-risk DTC patients that have undergone total thyroidectomy. R, recommendation in text.

<b>FIG. 6.</b>

**FIG. 6.

Clinical decision-making and management recommendations in ATA low risk DTC patients that have undergone less than total thyroidectomy (lobectomy or lobectomy with isthmusectomy). R, recommendation in text.

<b>FIG. 7.</b>

**FIG. 7.

Clinical decision-making and management recommendations in ATA intermediate risk DTC patients that have undergone total thyroidectomy. R, recommendation in text.

<b>FIG. 8.</b>

**FIG. 8.

Clinical decision-making and management recommendations in ATA high risk DTC patients that have undergone total thyroidectomy and have no gross residual disease remaining in the neck. R, recommendation in text.

Comment in

Similar articles

Cited by

References

    1. Vander JB, Gaston EA, Dawber TR. 1968. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 69:537–540 - PubMed
    1. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. 1977. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 7:481–493 - PubMed
    1. Tan GH, Gharib H. 1997. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126:226–231 - PubMed
    1. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. 2009. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 39:699–706 - PubMed
    1. Hegedus L. 2004. Clinical practice. The thyroid nodule. N Engl J Med 351:1764–1771 - PubMed

Publication types

MeSH terms

LinkOut - more resources